Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
Authors
Keywords
-
Journal
International Journal of Endocrinology
Volume 2013, Issue -, Pages 1-16
Publisher
Hindawi Limited
Online
2013-02-22
DOI
10.1155/2013/803171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preparation and in Vivo Evaluation of Liposomal Everolimus for Lung Carcinoma and Thyroid Carcinoma
- (2012) Yuko Iwase et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases
- (2012) A. Tamburrino et al. CLINICAL CANCER RESEARCH
- Prognostic and Predictive Markers in Medullary Thyroid Carcinoma
- (2012) Boban M. Erovic et al. ENDOCRINE PATHOLOGY
- Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells
- (2012) Joanna Klubo-Gwiezdzinska et al. ENDOCRINE-RELATED CANCER
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon
- (2012) A. Boichard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations inRETandRAS
- (2012) Nishant Agrawal et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line
- (2012) A. Vivaldi et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
- (2012) Joana P. Couto et al. PLoS One
- Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series
- (2012) Raffaele Ciampi et al. THYROID
- RET TKI: Potential Role in Thyroid Cancers
- (2012) Alessandro Antonelli et al. Current Oncology Reports
- Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer
- (2012) Maria Graziella Catalano et al. Frontiers in Endocrinology
- Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
- (2011) N. Jin et al. CLINICAL CANCER RESEARCH
- Vandetanib
- (2011) Helen Commander et al. DRUGS
- The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
- (2011) Hans H. G. Verbeek et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mammalian Target of Rapamycin Pathway Activation Is Associated to RET Mutation Status in Medullary Thyroid Carcinoma
- (2011) Ida Rapa et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas
- (2011) Margarida M. Moura et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapies for thyroid tumors
- (2011) Steven I Sherman MODERN PATHOLOGY
- Emerging therapies for thyroid carcinoma
- (2011) S. Walsh et al. SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND
- Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas
- (2011) Maria A. Kouvaraki et al. SURGERY
- Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
- (2010) Pierre-Yves Salaun et al. CANCER
- Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells
- (2010) Dumrongkiet Arthan et al. CANCER LETTERS
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
- (2010) Lei Ye et al. ENDOCRINE REVIEWS
- The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells
- (2010) D. Vitagliano et al. ENDOCRINE-RELATED CANCER
- Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes
- (2010) Cristina Romei et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Rapid Response to Sorafenib in Metastatic Medullary Thyroid Carcinoma
- (2010) K. Frank-Raue et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Do We Have to Change the Way Targeted Drugs Are Developed?
- (2010) Alberto Ocana et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU
- (2010) A. Ravaud et al. ONCOLOGIST
- Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma
- (2010) Clarissa Capp et al. THYROID
- Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis
- (2009) Cristina Rodríguez-Antona et al. ENDOCRINE-RELATED CANCER
- Medullary Thyroid Carcinoma Cell Lines Contain a Self-Renewing CD133+Population that Is Dependent on Ret Proto-Oncogene Activity
- (2009) Wen Zhu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma
- (2009) L. Santarpia et al. JOURNAL OF INTERNAL MEDICINE
- Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
- (2009) Aniello Cerrato et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells
- (2009) Simona Grozinsky-Glasberg et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
- (2009) Bachleitner-Hofmann ONCOLOGY REPORTS
- Targeted Anticancer Therapies: Mouse Models Help Uncover the Mechanisms of Tumor Escape
- (2008) Renée van Amerongen et al. CANCER CELL
- RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR
- (2008) M. Croyle et al. CANCER RESEARCH
- A Novel RET Kinase- -Catenin Signaling Pathway Contributes to Tumorigenesis in Thyroid Carcinoma
- (2008) T. S. Gujral et al. CANCER RESEARCH
- Amino Acid-Modified Calcitonin Immunization Induces Tumor Epitope-Specific Immunity in a Transgenic Mouse Model for Medullary Thyroid Carcinoma
- (2008) Margret Wuttke et al. ENDOCRINOLOGY
- Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
- (2008) Patricia M LoRusso et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer
- (2008) Maya B Lodish et al. Expert Review of Anticancer Therapy
- Dendritic Cell Vaccination Induces Tumor Epitope-specific Th1 Immune Response in Medullary Thyroid Carcinoma
- (2008) C. Papewalis et al. HORMONE AND METABOLIC RESEARCH
- Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers
- (2008) Zhi Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer
- (2008) Susan C. Pitt et al. SURGERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started